|
π
|
Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.
19 auth.
M. Scully,
M. Thomas,
M. Underwood,
H. Watson,
K. Langley,
R. Camilleri,
A. Clark,
D. Creagh,
R. Rayment,
V. Mcdonald,
...
A. Roy,
G. Evans,
Siobhan McGuckin,
F. N. NΓ Γinle,
R. Maclean,
W. Lester,
M. Nash,
R. Scott,
P. Oβ Brien
|
7 |
2014 |
7
π
|
|
π
|
REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT.
19 auth.
A. Cuker,
S. Cataland,
P. Coppo,
J. de la Rubia,
K. Friedman,
J. George,
P. Knoebl,
J. K. Kremer Hovinga,
Bernhard LΣmmle,
M. Matsumoto,
...
K. Pavenski,
F. Peyvandi,
K. Sakai,
R. Sarode,
M. Thomas,
Y. Tomiyama,
A. Veyradier,
J. Westwood,
M. Scully
|
6 |
2021 |
6
π
|
|
π
|
Conformational activation of ADAMTS13
9 auth.
K. South,
B. Luken,
J. Crawley,
R. Phillips,
M. Thomas,
R. Collins,
...
L. Deforche,
K. Vanhoorelbeke,
D. Lane
|
6 |
2014 |
6
π
|
|
π
|
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
28 auth.
F. Alwan,
C. Vendramin,
R. Liesner,
A. Clark,
W. Lester,
T. Dutt,
W. Thomas,
R. Gooding,
T. Biss,
Henry G. Watson,
N. Cooper,
R. Rayment,
T. Cranfield,
J. J. Veen,
Q. Hill,
...
Sarah Davis,
J. Motwani,
N. Bhatnagar,
Nicole Priddee,
M. DΓ‘vid,
Maeve P. Crowley,
J. Alamelu,
H. Lyall,
J. Westwood,
M. Thomas,
M. Thomas,
M. Scully,
M. Scully
|
6 |
2019 |
6
π
|
|
π
|
Characterization and treatment of congenital thrombotic thrombocytopenic purpura.
28 auth.
F. Alwan,
C. Vendramin,
R. Liesner,
A. Clark,
W. Lester,
T. Dutt,
W. Thomas,
R. Gooding,
T. Biss,
Henry G. Watson,
N. Cooper,
R. Rayment,
T. Cranfield,
J. J. Veen,
Q. Hill,
...
Sarah Davis,
J. Motwani,
N. Bhatnagar,
Nicole Priddee,
M. DΓ‘vid,
Maeve P. Crowley,
J. Alamelu,
H. Lyall,
J. Westwood,
M. Thomas,
M. Thomas,
M. Scully,
M. Scully
|
6 |
2019 |
6
π
|
|
π¦
|
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpuraβ
M. Thomas,
Rens de Groot,
M. Scully,
J. Crawley
|
6 |
2015 |
6
π¦
|
|
π
|
Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.
26 auth.
F. Alwan,
C. Vendramin,
K. Vanhoorelbeke,
K. Langley,
V. Mcdonald,
S. Austin,
A. Clark,
W. Lester,
R. Gooding,
T. Biss,
T. Dutt,
N. Cooper,
O. Chapman,
T. Cranfield,
K. Douglas,
...
H. Watson,
J. V. van Veen,
Keith R Sibson,
W. Thomas,
L. Manson,
Q. Hill,
S. Benjamin,
D. Ellis,
J. Westwood,
M. Thomas,
M. Scully
|
6 |
2017 |
6
π
|
|
π
|
Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.
10 auth.
J. Westwood,
M. Thomas,
F. Alwan,
V. Mcdonald,
S. Benjamin,
W. Lester,
...
G. Lowe,
T. Dutt,
Q. Hill,
M. Scully
|
6 |
2017 |
6
π
|
|
π
|
A phenotypeβgenotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom
8 auth.
R. Camilleri,
M. Scully,
M. Thomas,
I. Mackie,
R. Liesner,
W. Chen,
...
K. Manns,
S. Machin
|
6 |
2012 |
6
π
|
|
π
|
Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura
8 auth.
Christopher J. Patriquin,
M. Thomas,
T. Dutt,
Siobhan McGuckin,
P. Blombery,
T. Cranfield,
...
J. Westwood,
M. Scully
|
6 |
2016 |
6
π
|
